Research view
Switch to patient viewMyelodysplastic syndromes: trials that stopped early
Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
86 stopped trials give a reason in the registry, latest registry update first.
Terminated
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given in the registry “FDA Clinical Hold”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.
- Ended
- Oct 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02530034
Terminated
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Reason given in the registry “No longer have funding support to complete the pharmacogenetics component.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.
- Ended
- Mar 2025
- Phase
- Phase 2
- Run by
- Medical College of Wisconsin
- Registry record
- NCT03150004
Suspended
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Reason given in the registry “Accrual goal Met”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT03969446
Terminated
MBG453 in Lower Risk MDS
Reason given in the registry “The trial closed early due to changes in support for the study drug.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Ended
- Nov 2025
- Phase
- Phase 2
- Run by
- Massachusetts General Hospital
- Registry record
- NCT04823624
Suspended
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Reason given in the registry “resources”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06454409
Suspended
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Timeline Adjustment”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06195891
Suspended
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Reason given in the registry “Funding unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2026.
- Phase
- Phase 2
- Run by
- Abhay Singh, MD MPH
- Registry record
- NCT06630221
Suspended
Ascorbate in Myelodysplastic Syndrome
Reason given in the registry “temporary suspension”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2026.
- Phase
- Phase 2
- Run by
- Prajwal Dhakal
- Registry record
- NCT07283900
Withdrawn
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Reason given in the registry “PI request”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.
- Ended
- Jun 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06597734
Terminated
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Inability to meet protocol objectives”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.
- Ended
- Aug 2026
- Phase
- Phase 1
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT06419634
Terminated
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Reason given in the registry “RPD2 has been identified”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.
- Ended
- May 2024
- Phase
- Phase 1
- Run by
- Ryvu Therapeutics SA
- Registry record
- NCT04021368
Terminated
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- Ryvu Therapeutics SA
- Registry record
- NCT06268574
Suspended
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Reason given in the registry “insufficient funding”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.
- Phase
- Phase 2
- Run by
- Leland Metheny
- Registry record
- NCT06680661
Suspended
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Reason given in the registry “Drug Supply Issues”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Sept 2026.
- Phase
- Phase 1
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06888323
Terminated
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Reason given in the registry “Futility assessment concluded low likelihood of the trial showing meaningful patient benefit.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2026.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Forma Therapeutics, Inc.
- Registry record
- NCT05568225
Terminated
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Reason given in the registry “\<75% participants”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2026.
- Ended
- Aug 2026
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02392572
Withdrawn
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Reason given in the registry “FDA requested significant changes to the study protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Aug 2026.
- Phase
- Phase 1/2
- Run by
- Thomas Jefferson University
- Registry record
- NCT07387354
Suspended
DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Reason given in the registry “Recruitment on hold with plans to open to accrual again soon.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Aug 2026.
- Phase
- Phase 1
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT06492707
Terminated
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Reason given in the registry “The study was closed due to the end of funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Aug 2026.
- Ended
- Jul 2026
- Phase
- Phase 2
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT04994808
Terminated
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Reason given in the registry “Slow participant enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2026.
- Ended
- Mar 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06021600
Suspended
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Reason given in the registry “Funding Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Jul 2026.
- Phase
- Phase 1/2
- Run by
- Mikkael Sekeres, MD
- Registry record
- NCT04539236
Suspended
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Reason given in the registry “Drugs unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.
- Phase
- Phase 1
- Run by
- David Wald
- Registry record
- NCT05400122
Withdrawn
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Reason given in the registry “The study has not actually been conducted.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Jul 2026.
- Phase
- Phase 1/2
- Run by
- Peking Union Medical College Hospital
- Registry record
- NCT06020833
Terminated
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
Reason given in the registry “Insufficient enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Jul 2026.
- Ended
- May 2025
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT07681440
Terminated
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2026.
- Ended
- May 2026
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04550442
Terminated
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given in the registry “No longer a research question to answer.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.
- Ended
- May 2026
- Run by
- Masonic Cancer Center, University of Minnesota
- Registry record
- NCT01962636
Terminated
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given in the registry “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT03246906
Suspended
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
Reason given in the registry “Others”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.
- Phase
- Phase 1/2
- Run by
- Sclnow Biotechnology Co., Ltd.
- Registry record
- NCT03184935
Terminated
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Reason given in the registry “Patient recruitment problems.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Aurigene Discovery Technologies Limited
- Registry record
- NCT05607199
Terminated
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Adjusted the product development strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Registry record
- NCT05263271
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.